Necitumumab (INN: Necitumumab) is a recombinant human IgG1 monoclonal antibody used as an anti-tumor drug and produced by Eli Lilly and Company. It binds to the epidermal growth factor receptor (EGFR). The U.S. Food and Drug Administration approves nesituzumab (brand name Portrazza), along with gemcitabine and cisplatin, for the treatment of untreated metastatic squamous non-small cell lung cancer (NSCLC).
Let us work together to protect precious health